Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Using urine microscopy and cytology for early detection of bladder cancer in male patients with lower urinary tract symptoms

Abstract

Objectives

Irritative urinary symptoms and micro-hematuria are the common findings in bladder cancer patients. In this study, we investigated the use of urine microscopy and cytological examination for early detection of bladder cancer in patients with lower urinary tract symptoms (LUTS).

Methods

Male patients presented with LUTS to urology clinic were enrolled. Voiding symptoms were evaluated with international prostate symptoms score, and urine samples were collected for microscopy and cytological examination. Cystoscopy was performed in patients with microscopic hematuria, suspicious/malignant cells in urine or at the time of transurethral resection of prostate. Subjects, who had no indication and did not receive cystoscopy, were followed up in clinic for progress of symptoms, including gross hematuria and occurrence of bladder cancer.

Results

Nine hundred and eighty-eight patients were enrolled during the period of 2005–2007. Fifty-two (5.26%) urine samples were documented as atypical, and 936 (94.7%) were negative. There was no suspicious or malignant cytology result in this series. Micro-hematuria was noticed in six patients (0.61%). The mean follow-up time was 29.1 ± 12.5 months. One (0.10%) patient had bladder cancer 44 months after the first visit in the cohort, who had micro-hematuria, atypical urine cytology, but normal cystoscopy before diagnosis.

Conclusion

The prevalence rate of bladder cancer in male patients with LUTS is low. This study adds to information that microscopy and cytological examination are not useful to detect bladder cancer. Due to the economic concerns and burden of unnecessary investigations, the routine use of these tests is in doubt.

This is a preview of subscription content, log in to check access.

Abbreviations

LUTS:

Lower urinary tract symptoms

CIS:

Carcinoma in situ

IPSS:

International prostate symptoms score

BPH:

Benign prostate hyperplasia

TURP:

Transurethral resection of prostate

PPV:

Positive predictive value

References

  1. 1.

    Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96

  2. 2.

    Hong Kong Cancer Stat 2006. Hong Kong Cancer Registry, Hospital Authority. http://www3.ha.org.hk/cancereg/. Cited 18 May 2010

  3. 3.

    Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M et al (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46(5):547–554

  4. 4.

    AUA Practice Guidelines Committee, authors (2003) AUA guideline on management of benign prostatic hyperplasia 2003, chapter 1: diagnosis and treatment recommendations. J Urol 170(2 pt 1): 530–547

  5. 5.

    Grossfeld GD, Carroll PR (1998) Evaluation of asymptomatic microscopic hematuria. Urol Clin North Am 25(4):661–676

  6. 6.

    Papanicolaou GN, Marshall VF (1945) Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 101(2629):519–520

  7. 7.

    Varkarakis MJ, Gaeta J, Moore RH et al (1974) Superficial bladder tumor. Aspects of clinical progression. Urology 4(4):414–420

  8. 8.

    Yip SK, Peh WC, Tam PC et al (1998) Day case hematuria diagnostic service: use of ultrasonography and flexible cystoscopy. Urology 52(5):762–766

  9. 9.

    Farrow GM, Utz DC, Rife CC et al (1977) Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 37(8 Pt 2):2794–2798

  10. 10.

    Messing EM, Young TB, Hunt VB et al. (1995) Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45(3):387–396; discussion 396–397

  11. 11.

    Thompson IM (1987) The evaluation of microscopic hematuria: a population-based study. J Urol 138(5):1189–1190

  12. 12.

    Ritchie CD, Bevan EA, Collier SJ (1986) Importance of occult haematuria found at screening. Br Med J 292(6521):681–683

  13. 13.

    Hiatt RA, Ordoñez JD (1994) Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample. Cancer Epidemiol Biomarkers Prev 3(5):439–443

  14. 14.

    Golin AL, Howard RS (1980) Asymptomatic microscopic hematuria. J Urol 124:389

  15. 15.

    Mohr DN, Offord KP, Owen RA et al (1986) Asymptomatic micro-hematuria and urologic disease. A population-based study. JAMA 256:224

  16. 16.

    Messing EM, Vaillancourt A (1990) Hematuria screening for bladder cancer. J Occup Med 32:838

  17. 17.

    Kroft SH, Oyasu R (1994) Urinary bladder cancer: mechanisms of development and progression. Lab Invest 71(2):158–174

  18. 18.

    Svatek RS, Lotan Y (2008) Is there a rationale for bladder cancer screening? Curr Urol Rep 9(5):339–341

  19. 19.

    Lotan Y, Svatek RS, Malats N (2008) Screening for bladder cancer: a perspective. World J Urol 26(1):13–18

  20. 20.

    Potter JM, Quigley M, Pengelly AW (1999) The role of urine cytology in the assessment of lower urinary tract symptoms. BJU Int 84(1):30–31

  21. 21.

    de la Rosette JJ, Hubregtse MR, Wiersma AM (1993) Value of urine cytology in screening patients with prostatitis syndromes. Acta Cytol 37(5):710–712

  22. 22.

    Hofland CA, Mariani AJ (2004) Is cytology required for a hematuria evaluation? J Urol 171(1):324–326

  23. 23.

    Lotan Y, Svatek RS, Sagalowsky AI (2006) Should we screen for bladder cancer in a high-risk population? a cost per life-year saved analysis. Cancer 107(5):982–990

  24. 24.

    Badalament RA, Hermansen DK, Kimmel M (1987) The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 60(7):1423–1427

  25. 25.

    Hong YM, Loughlin KR (2008) Economic impact of tumor markers in bladder cancer surveillance. Urology 71(1):131–135

  26. 26.

    Têtu B (2009) Diagnosis of urothelial carcinoma from urine. Mod Pathol 22:S53–S59

  27. 27.

    Daniely M, Rona R, Kaplan T (2007) Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer 111(6):517–524

  28. 28.

    Marshall VF (1956) Current clinical problems regarding bladder tumors. Cancer 9(3):543–550

  29. 29.

    Lee R, Droller MJ (2000) The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 27(1):1–13

Download references

Author information

Correspondence to Eddie S. Y. Chan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chan, E.S.Y., Ng, C., Hou, S. et al. Using urine microscopy and cytology for early detection of bladder cancer in male patients with lower urinary tract symptoms. Int Urol Nephrol 43, 289–294 (2011). https://doi.org/10.1007/s11255-010-9856-y

Download citation

Keywords

  • Bladder cancer
  • Urine cytology
  • Urine microscopy
  • Screening
  • LUTS